Prior therapies have focused on effects, not on causes. They have tried to help symptoms or wished to remove amyloid or tau proteins.
Research shows that cell aging triggers the gradual accumulation of amyloid, as well as the loss of neurons that defines Alzheimer’s.
Telomerase resets the abnormal pattern of gene expression that results in Alzheimer’s disease. We can make a difference. Join us.
Dr. Fossel is the driving force behind Telocyte and has been the leader in proposing the use of telomerase to treat human disease for the past two decades.
Peter T. Rayson is an experienced industry executive who provides leadership and business acumen for Telocyte.
Telocyte and CNIO have signed an MOU for collaboration to investigate the use of Telomerase Therapy to cure Alzheimer’s.
Under the direction of Dr. Maria Blasco, C.N.I.O. – The Spanish National Research Centre, has recently made advances in both animal research and delivery systems that has facilitated an opportunity to pursue unsurpassed clinical advances in the field of telomerase therapy. Dr. Blasco is an internationally recognized expert in the field of telomerase
Published in the pre-eminent scientific journal EMBO, this article demonstrated the efficacy of telomerase therapy in treating aging in animals, without any evidence of side effects.